Ordering and reimbursement

TAGRISSO ordering information

Order Form/Service Request Form

download download

Distribution Information

download download

Help your patients access TAGRISSO

download download

See which specialty pharmacies distribute TAGRISSO

FPO Graph FPO Graph
AstraZeneca Access 360 Logo AstraZeneca Access 360 Logo

Helping patients access the care they need

The AstraZeneca Access 360 program provides personal support to connect patients to affordability programs and streamline access and reimbursement for TAGRISSO.

Access 360 provides:

  • Assistance with understanding patient insurance coverage and pharmacy options
  • Prior authorization support
  • Claims and appeal process support
  • Eligibility requirements and enrollment assistance for specialty Patient Savings Programs
  • Referrals to patient assistance programs
  • Referrals to nurse assistance or educational support programs, if applicable

To learn more about the AstraZeneca Access 360 program, please call 1-844-ASK-A360 (1-844-275-2360) Monday - Friday 8 AM - 8 PM EST or visit www.MyAccess360.com.

TAGRISSO Affordability Brochure

download download

Coding Resource

download download

Helpful resources for you and your patients

Convenient downloads for your practice

Helpful information for patients as they begin TAGRISSO therapy

Download the full brochure

download download

Organizations offering patient support

Download the advocacy organizations list

download download

See other ways TAGRISSO offers support for your patients on Facebook.

Organizations that you and your patients may find helpful

Professional Organizations

American Society of Clinical Oncologists (ASCO)

National Comprehensive Cancer Network® (NCCN®)

Oncology Nursing Society

The ONC: The Oncology Nursing Community

TAGRISSO Nurse Resource

This webpage is a resource, specifically designed for nurses, to help patients and their caregivers learn more about TAGRISSO and how patients may benefit from treatment. It aids nurses in communicating helpful information about dosing, support and access for TAGRISSO, and to enable the early identification and management of potential adverse reactions.

Important Safety Information Expand

  • There are no contraindications for TAGRISSO

  • Interstitial lung disease (ILD)/pneumonitis occurred in 3.9% of the 1142 TAGRISSO-treated patients; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed

  • Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1142 TAGRISSO-treated patients in clinical trials, 0.9% were found to have a QTc > 500 msec, and 3.6% of patients had an increase from baseline QTc > 60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia

  • Cardiomyopathy occurred in 2.6% of the 1142 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 3.9% of 908 patients who had baseline and at least one follow-up LVEF assessment. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO

  • Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist

  • Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose

  • Most common adverse reactions (≥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite

Indications

  • TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test

  • TAGRISSO is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy


Please see complete Prescribing Information including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.

read more